"Folic Acid Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033)
| Descriptor ID |
D005493
|
| MeSH Number(s) |
D27.505.519.389.350
|
| Concept/Terms |
Folic Acid Antagonists- Folic Acid Antagonists
- Acid Antagonists, Folic
- Antagonists, Folic Acid
- Dihydrofolate Reductase Inhibitors
- Inhibitors, Dihydrofolate Reductase
- Reductase Inhibitors, Dihydrofolate
- Antifolates
|
Below are MeSH descriptors whose meaning is more general than "Folic Acid Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Folic Acid Antagonists".
This graph shows the total number of publications written about "Folic Acid Antagonists" by people in this website by year, and whether "Folic Acid Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2012 | 3 | 0 | 3 |
| 2014 | 3 | 0 | 3 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Folic Acid Antagonists" by people in Profiles.
-
Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents. Bioorg Med Chem Lett. 2017 04 01; 27(7):1602-1607.
-
Modified 2,4-diaminopyrimidine-based dihydrofolate reductase inhibitors as potential drug scaffolds against Bacillus anthracis. Bioorg Med Chem. 2015 Jan 01; 23(1):203-11.
-
Synthesis and biological evaluation of 2,4-diaminopyrimidine-based antifolate drugs against Bacillus anthracis. Molecules. 2014 Mar 17; 19(3):3231-46.
-
The structure and competitive substrate inhibition of dihydrofolate reductase from Enterococcus faecalis reveal restrictions to cofactor docking. Biochemistry. 2014 Feb 25; 53(7):1228-38.
-
Structure-activity relationship for enantiomers of potent inhibitors of B. anthracis dihydrofolate reductase. Biochim Biophys Acta. 2013 Jan; 1834(1):46-52.
-
Inhibition of bacterial dihydrofolate reductase by 6-alkyl-2,4-diaminopyrimidines. ChemMedChem. 2012 Nov; 7(11):1974-82.
-
Synthesis and biological activity of substituted 2,4-diaminopyrimidines that inhibit Bacillus anthracis. Eur J Med Chem. 2012 Aug; 54:387-96.
-
Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009 Jun 01; 27(16):2686-91.
-
Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity. Bioorg Med Chem. 2005 Sep 15; 13(18):5475-91.
-
A phase II trial of edatrexate in previously treated squamous cell cervical cancer: a Gynecologic Oncology Group study. Am J Clin Oncol. 1997 Feb; 20(1):78-80.